ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants

Signal Transduct Target Ther. 2022 Feb 9;7(1):43. doi: 10.1038/s41392-022-00913-3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme 2 / antagonists & inhibitors*
  • Angiotensin-Converting Enzyme 2 / genetics
  • Angiotensin-Converting Enzyme 2 / immunology
  • Animals
  • Antibodies, Neutralizing / pharmacology*
  • Antibodies, Viral / pharmacology*
  • COVID-19 / immunology
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Enzyme-Linked Immunosorbent Assay
  • Gene Expression
  • Host-Pathogen Interactions / genetics
  • Host-Pathogen Interactions / immunology
  • Humans
  • Lung / drug effects
  • Lung / immunology
  • Lung / virology
  • Mice
  • Protein Binding / drug effects
  • Receptors, Virus / antagonists & inhibitors*
  • Receptors, Virus / genetics
  • Receptors, Virus / immunology
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / growth & development
  • SARS-CoV-2 / immunology
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Receptors, Virus
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2

Supplementary concepts

  • SARS-CoV-2 variants